Booster vaccination strategy: Necessity, Immunization Objectives, Immunization Strategy and Safety

SUMMARYThe aim of this study was to investigate the optimal pertussis booster vaccination strategy for The Netherlands. A realistic age-structured deterministic model was designed. Assuming a steady-state situation and correcting for underreporting, the model was calibrated using notification data from the period 1996–2000. Several sensitivity analyses were performed to explore the impact of different assumptions for parameters surrounded by uncertainty (e.g. duration of protection after natural infection, underreporting factors, and transmission probabilities). The optimal age of an additional booster dose is in the range of 10–15 years, and implementation of this booster dose will reduce both symptomatic and asymptomatic infections, although the incidence of symptomatic infections in older age groups will increase. The impact of the different assumptions used in the model was in general limited. We conclude that over a wide range of assumptions, an additional booster dose can reduce the incidence of pertussis in the population.

Download Full-text

Enhanced Immunogenicity in the Murine Airway Mucosa with an Attenuated Salmonella Live Vaccine Expressing OprF-OprI from Pseudomonas aeruginosa

Infection and Immunity ◽

10.1128/iai.72.11.6546-6553.2004 ◽

2004 ◽

Vol 72 (11) ◽

pp. 6546-6553 ◽

Cited By ~ 21

Author(s):

Heinz Arnold ◽

Dirk Bumann ◽

Melanie Felies ◽

Britta Gewecke ◽

Meike Sörensen ◽

...

Keyword(s):

Pseudomonas Aeruginosa ◽

Outer Membrane Proteins ◽

Immunoglobulin A ◽

Vaccination Strategy ◽

Booster Vaccination ◽

Primary Vaccination ◽

Live Vaccine ◽

Igg Antibody ◽

Inducible Protein

ABSTRACT We constructed an oral live vaccine based on the attenuated aroA mutant Salmonella enterica serovar Typhimurium strain SL3261 expressing outer membrane proteins F and I (OprF-OprI) from Pseudomonas aeruginosa and investigated it in a mouse model. Strains with in vivo inducible protein expression with the P pacC promoter showed good infection rates and immunogenicity but failed to engender detectable antibodies in the lung. However, a systemic booster vaccination following an oral primary immunization yielded high immunoglobulin A (IgA) and IgG antibody levels in both upper and lower airways superior to conventional systemic or mucosal booster vaccination alone. In addition, the proportion of IgG1 and IgG2a antibodies suggested that the systemic booster does not alter the more TH1-like type of response induced by the oral Salmonella primary vaccination. We conclude that an oral primary systemic booster vaccination strategy with an appropriate mucosal vector may be advantageous in diseases with the risk of P. aeruginosa airway infection, such as cystic fibrosis.

Download Full-text

A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine

The Pediatric Infectious Disease Journal ◽

10.1097/inf.0000000000001535 ◽

2017 ◽

Vol 36 (5) ◽

pp. e157-e161 ◽

Cited By ~ 1

Author(s):

Fangjun Li ◽

Yuansheng Hu ◽

Youming Zhou ◽

Lixin Chen ◽

Wei Xia ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Hepatitis B ◽

Hepatitis A ◽

Controlled Trial ◽

Vaccination Strategy ◽

Booster Vaccination ◽

Randomized Controlled

Download Full-text

Measuring the impact of COVID-19 vaccination and immunity waning: a modelling study for Portugal

10.1101/2021.12.10.21267618 ◽

2021 ◽

Author(s):

Constantino Caetano ◽

Maria Luisa Morgado ◽

Paula Patricio ◽

Andreia Leite ◽

Ausenda Machado ◽

...

Keyword(s):

Deterministic Model ◽

Vaccination Strategy ◽

Booster Vaccination ◽

Vaccine Effectiveness ◽

Disease Spread ◽

Peak Reduction ◽

Substantial Impact ◽

Control Disease ◽

Lower Magnitude ◽

The Impact

Vaccination strategies to control COVID-19 have been ongoing worldwide since the end of 2020. Understanding their possible effect is key to prevent future disease spread. Using a modelling approach, this study intends to measure the impact of the COVID-19 Portuguese vaccination strategy on the effective reproduction number and explore three scenarios for vaccine effectiveness waning. Namely, the no-immunity-loss, 1-year and 3-years of immunity duration scenarios. We adapted an age-structured SEIR deterministic model and used Portuguese hospitalisation data for the model calibration. Results show that, although the Portuguese vaccination plan had a substantial impact in reducing overall transmission, it might not be sufficient to control disease spread. A significant vaccination coverage of those above 5 years old, a vaccine effectiveness against disease of at least 80% and softer non-pharmaceutical interventions (NPIs), such as mask usage and social distancing, would be necessary to control disease spread in the worst scenario considered. The immunity duration scenario of 1-year displays a resurgence of COVID-19 hospitalisations by the end of 2021, the same is observed in 3-year scenario although with a lower magnitude. The no-immunity-loss scenario presents a low increase in hospitalisations. In both the 1-year and 3-year scenarios, a vaccination boost of those above 65 years old would result in a 53% and 38% peak reduction of non-ICU hospitalisations, respectively. These results suggest that NPIs should not be fully phased-out but instead be combined with a fast booster vaccination strategy to reduce healthcare burden.

Download Full-text

Immune Responses of Bison and Efficacy after Booster Vaccination with Brucella abortus Strain RB51

Clinical and Vaccine Immunology ◽

10.1128/cvi.00746-14 ◽

2015 ◽

Vol 22 (4) ◽

pp. 440-447 ◽

Cited By ~ 4

Author(s):

S. C. Olsen ◽

J. L. McGill ◽

R. E. Sacco ◽

S. G. Hennager

Keyword(s):

Brucella Abortus ◽

Mononuclear Cells ◽

Herd Immunity ◽

Vaccination Strategy ◽

Booster Vaccination ◽

Peripheral Blood Mononuclear ◽

Content Type ◽

Single Vaccination ◽

Ifn Γ

ABSTRACTThirty-one bison heifers were randomly assigned to receive saline or a single vaccination with 1010CFU ofBrucella abortusstrain RB51. Some vaccinated bison were randomly selected for booster vaccination with RB51 at 11 months after the initial vaccination. Mean antibody responses to RB51 were greater (P< 0.05) in vaccinated bison after initial and booster vaccination than in nonvaccinated bison. The proliferative responses by peripheral blood mononuclear cells (PBMC) from the vaccinated bison were greater (P< 0.05) than those in the nonvaccinated bison at 16 and 24 weeks after the initial vaccination but not after the booster vaccination. The relative gene expression of gamma interferon (IFN-γ) was increased (P< 0.05) in the RB51-vaccinated bison at 8, 16, and 24 weeks after the initial vaccination and at 8 weeks after the booster vaccination. The vaccinated bison had greater (P< 0.05)in vitroproduction of IFN-γ at all sampling times, greater interleukin-1β (IL-1β) production in various samplings after the initial and booster vaccinations, and greater IL-6 production at one sampling time after the booster vaccination. Between 170 and 180 days of gestation, the bison were intraconjunctivally challenged with approximately 1 × 107CFU ofB. abortusstrain 2308. The incidences of abortion and infection were greater (P< 0.05) in the nonvaccinated bison after experimental challenge than in the bison receiving either vaccination treatment. Booster-vaccinated, but not single-vaccinated bison, had a reduced (P< 0.05) incidence of infection in fetal tissues and maternal tissues compared to that in the controls. Compared to the nonvaccinated bison, both vaccination treatments lowered the colonization (measured as the CFU/g of tissue) ofBrucellaorganisms in all tissues, except in retropharyngeal and supramammary lymph nodes. Our study suggests that RB51 booster vaccination is an effective vaccination strategy for enhancing herd immunity against brucellosis in bison.

Download Full-text

Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation

Frontiers in Oncology ◽

10.3389/fonc.2021.752444 ◽

2021 ◽

Vol 11 ◽

Author(s):

Chenlu Liu ◽

Xianling Cong ◽

Yuqian Wang ◽

Qianqian Guo ◽

Yu Xie ◽

...

Keyword(s):

Immune Response ◽

Dna Vaccine ◽

Vaccination Strategy ◽

Memory Cell ◽

Underlying Mechanism ◽

Dna Vaccination ◽

Antitumor Effects ◽

Immunization Strategy ◽

Effector Cells ◽

Lung Cancer Model

Conventional DNA vaccine strategies usually employ a regimen of immunizations at 2-week or longer intervals to induce effective memory cell-dependent immune responses. Clinical cancer treatment requires a faster immunization strategy to contend with tumor progression. In this study, a novel fast immunization strategy was established, wherein a DNA vaccine was intramuscularly administered on days 0, 2, and 5 in a murine lung cancer model. Effector cells peaked 7 to 10 days after the last vaccination. Compared with traditional 2-week-interval immunization strategies, antigen-specific cytolysis and INF-γ secretion were significantly enhanced under the fast vaccination approach. As a result, the rapidly administered DNA vaccine elicited stronger and more prompt antitumor effects. The probable underlying mechanism of fast immunization was the accumulation of CD8+CD11c+ antigen-presenting cells at the injection site, which enhanced subsequent antigen presentation. In conclusion, the fast DNA vaccination strategy shortened vaccination time to 5 days and elicited a stronger antitumor immune response.

Download Full-text

Heterologous vaccination strategy for containing COVID-19 pandemic

10.1101/2021.05.17.21257134 ◽

2021 ◽

Author(s):

Ang Lin ◽

Jingjing Liu ◽

Xiaopin Ma ◽

Fanfan Zhao ◽

Bo Yu ◽

...

Keyword(s):

Vaccine Candidate ◽

Vaccination Strategy ◽

Proof Of Concept ◽

Healthy Individuals ◽

Vaccination Regimen ◽

Immunization Strategy ◽

Vaccine Responses ◽

Cell Responses ◽

Report Data ◽

Heterologous Boost

An unequitable vaccine allocation and continuously emerging SARS-CoV-2 variants pose challenges to contain the pandemic, which underscores the need for licensing more vaccine candidates, increasing manufacturing capacity and implementing better immunization strategy. Here, we report data from a proof-of-concept investigation in two healthy individuals who received two doses of inactivated whole-virus COVID-19 vaccines, followed by a single heterologous boost vaccination after 7 months with an mRNA vaccine candidate (LPP-Spike-mRNA) developed by Stemirna Therapeutics. Following the boost, Spike-specific antibody (Ab), memory B cell and T cell responses were significantly increased. These findings indicate that a heterologous immunization strategy combining inactivated and mRNA vaccines can generate robust vaccine responses and therefore provide a rational and effective vaccination regimen.

Download Full-text